The North America Guillain-Barre Syndrome Market would witness market growth of 4.1% CAGR during the forecast period (2023-2030).
The US market dominated the North America Guillain-Barre Syndrome Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $211,863.5 Thousands by 2030. The Canada market is experiencing a CAGR of 6.4% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 5.5% during (2023 - 2030).
The aging population has a significant impact on GBS. It primarily affects adults, with the highest incidence rates observed in individuals aged 50 and older. As the global population continues to age, there is a natural increase in the number of people at risk for GBS, contributing to the overall burden of the disease.
Additionally, by the Pan American Health Organization, more than 30 million individuals in Brazil were 60 years of age or elderly, accounting for 13 percent of the country’s total population. By 2030, this age group will comprise 24 percent of the Brazilian population or approximately 50 million individuals.
As per the Government of Canada, in 2023, the government announced an investment of $196.1 billion over ten years, including $46.2 billion in new funding, for provinces and territories to improve health care services for Canadians. In addition, it will invest $2.5 billion over ten years to support indigenous priorities and complementary federal support, for a total of $198.6 billion over ten years.
Based on Therapeutics, the market is segmented into Intravenous Immunoglobulin, Plasma Exchange, and Others. Based on Route of Administration, the market is segmented into Parenteral, and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The US market dominated the North America Guillain-Barre Syndrome Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $211,863.5 Thousands by 2030. The Canada market is experiencing a CAGR of 6.4% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 5.5% during (2023 - 2030).
The aging population has a significant impact on GBS. It primarily affects adults, with the highest incidence rates observed in individuals aged 50 and older. As the global population continues to age, there is a natural increase in the number of people at risk for GBS, contributing to the overall burden of the disease.
Additionally, by the Pan American Health Organization, more than 30 million individuals in Brazil were 60 years of age or elderly, accounting for 13 percent of the country’s total population. By 2030, this age group will comprise 24 percent of the Brazilian population or approximately 50 million individuals.
As per the Government of Canada, in 2023, the government announced an investment of $196.1 billion over ten years, including $46.2 billion in new funding, for provinces and territories to improve health care services for Canadians. In addition, it will invest $2.5 billion over ten years to support indigenous priorities and complementary federal support, for a total of $198.6 billion over ten years.
Based on Therapeutics, the market is segmented into Intravenous Immunoglobulin, Plasma Exchange, and Others. Based on Route of Administration, the market is segmented into Parenteral, and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
List of Key Companies Profiled
- F.Hoffmann-La Roche Ltd.
- Pfizer, Inc.
- PTC, Inc.
- AstraZeneca PLC
- Novartis AG
- Novo Nordisk A/S
- Takeda Pharmaceutical Company Limited
- Bayer AG
- Merck & Co., Inc.
- Bristol Myers Squibb Company
Market Report Segmentation
By Therapeutics- Intravenous Immunoglobulin
- Plasma Exchange
- Others
- Parenteral
- Oral
- Hospital Pharmacies
- Retail Pharmacies
- Others
- US
- Canada
- Mexico
- Rest of North America
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. North America Guillain-Barre Syndrome Market by Therapeutics
Chapter 5. North America Guillain-Barre Syndrome Market by Route Of Administration
Chapter 6. North America Guillain-Barre Syndrome Market by Distribution Channel
Chapter 7. North America Guillain-Barre Syndrome Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
- Pfizer, Inc.
- PTC, Inc.
- AstraZeneca PLC
- Novartis AG
- Novo Nordisk A/S
- Takeda Pharmaceutical Company Limited
- Bayer AG
- Merck & Co., Inc.
- Bristol Myers Squibb Company
Methodology
LOADING...
